Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Linex
- Development stage
- Unknown
- Lead developer
- Lek
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Linex** is an oral probiotic medicinal product containing live lyophilized *Bifidobacterium infantis*, *Enterococcus faecium*, and *Lactobacillus acidophilus*. It is intended to support restoration and maintenance of intestinal microbial balance and is used as preventive or supportive therapy for diarrhea, flatulence, and other digestive disturbances associated with disruption of the intestinal microbiota, including after gastrointestinal infections or antimicrobial treatment. The viable bacteria acidify the intestinal environment through carbohydrate fermentation and may inhibit overgrowth of pathogenic organisms while supporting normal gut microbial function. ([gnh-usa.com](https://www.gnh-usa.com/products/linex-enterococcus-faecium-lactobacillus-acidophilus-bifidobacterium-infantis-9))
- Brand names
- Linex
- Other names
- Bifidobacterium infantis + Enterococcus faecium + Lactobacillus acidophilusLactobacillus acidophilus + Bifidobacterium infantis + Enterococcus faecium
Beyond the preview
Go deeper on Linex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Linex.